Welcome to our dedicated page for Cartesian news (Ticker: RNAC), a resource for investors and traders seeking the latest updates and insights on Cartesian stock.
Cartesian Therapeutics, Inc. reports news on its late clinical-stage biotechnology work in mRNA-engineered cell therapy for autoimmune diseases. The company's lead asset, Descartes-08, is an autologous BCMA-targeting CAR-T candidate being developed for generalized myasthenia gravis, myositis indications such as dermatomyositis and antisynthetase syndrome, and pediatric autoimmune diseases including juvenile dermatomyositis.
Recurring updates cover clinical program progress across AURORA, TRITON and HELIOS, FDA designations for Descartes-08, financial results and cash runway commentary, corporate presentations and investor conference participation. News also includes Nasdaq employment inducement grants, equity incentive plan activity, and board or committee changes tied to the company's public-company governance.
Summary not available.
Summary not available.